You are here

Article Text

Article menu
Download PDFPDF
Original Article
Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy
  1. Yoshinori Mitamuraa,
  2. Shinobu Takeuchia,
  3. Akira Matsudab,
  4. Yoshitsugu Tagawab,
  5. Yuka Mizued,
  6. Jun Nishihirac
  1. aDepartment of Ophthalmology, Toho University Sakura Hospital, Sakura, Japan, bDepartment of Ophthalmology, Hokkaido University School of Medicine, Sapporo, Japan, cCentral Research Institute, Hokkaido University School of Medicine, Sapporo, Japan, dSapporo Immunodiagnostic Laboratory, Sapporo, Japan
  1. Yoshinori Mitamura, MD, Department of Ophthalmology, Toho University Sakura Hospital, 564-1 Shimoshizu, Sakura, Chiba 285-8741, Japanophtsakura{at}i.bekkoame.ne.jp

Abstract

AIMS To assess the potential role of macrophage migration inhibitory factor (MIF) in the pathogenesis of proliferative diabetic retinopathy (PDR).

METHODS MIF levels were assayed in the vitreous and paired serum samples of 73 consecutive patients with PDR (32 eyes) and macular hole or idiopathic epiretinal membrane (controls, 41 eyes). An enzyme linked immunosorbent assay technique was used to determine the concentrations of MIF.

RESULTS The median vitreous level of MIF was 11.93 ng/ml (range 4.16–103.85) in the patients with PDR, and 1.79 ng/ml (undetectable–8.93) in the controls. Vitreous levels in eyes with PDR were significantly greater than those in the controls (p<0.0001). Vitreous levels were significantly higher than serum levels in eyes with PDR (p=0.0026). MIF levels were significantly higher in the vitreous of PDR patients with severe fibrous proliferation than in those with slight proliferation (p<0.05).

CONCLUSION The results indicate increased levels of MIF in the vitreous of patients with PDR and a significant association between MIF levels and grades of fibrous proliferation, suggesting the possibility that MIF may play a part in the development of the proliferative phase of PDR.

  • macrophage migration inhibitory factor
  • proliferative diabetic retinopathy
  • vitreous

https://doi.org/10.1136/bjo.84.6.636

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes